Novartis has announced the
approval for pre-qualification of
its malaria treatment Coartem
80/480mg, opening up greater
access for patients.
Coartem is the first and only high
strength (80/480mg) Artemisininbased
Combination Therapy (ACT)
antimalarial treatment available for
public sector procurement.
The availability of this product
may be able to help relieve
suffering for as many as 25 million
African malaria patients, Novartis
said.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jul 15
THE Australian Commission on Safety and Quality in Health Care has today launched a national Standard to improve the care of people with cognitive disabilities or impairments.
AUSTRALIAN mothers and their babies experienced some positive outcomes during the early years of the pandemic, new research from the Australian Institute of Health and Welfare (AIHW) has discovered.
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.